Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07378839

Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting

This is a prospective, two-arm, non-blinded randomized controlled study designed to evaluate the effects of a one-week alternate nostril breathing (ANB) intervention on nausea and vomiting severity in pregnant individuals during their first trimester.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pregnancy Emesis Nausea Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Location status: Recruiting

Location contact

Erin Wesley

CONTACT

[email protected]

612-624-9208

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant individuals aged 18 years or older
  • Viable pregnancy with a gestational age between 6 0/7 - 12 6/7 weeks of gestation, confirmed by last menstrual period or ultrasound
  • Diagnosed with mild to moderate NVP (PUQE-24 score between 4-12)
  • Ability to understand and read English

Exclusion criteria

  • Severe nausea and vomiting, defined as a PUQE score >12, or diagnosis of hyperemesis gravidarum requiring hospitalization or intravenous fluid therapy
  • Pre-existing, active or acute respiratory conditions (e.g., asthma, COPD)
  • History of severe anxiety disorders affecting breathing patterns
  • Known deviated nasal septum
  • Nausea and vomiting that pre-dates the pregnancy or is suspected to be due to a etiology other than pregnancy

Treatment and study plan

Alternate Nostril Breathing

Behavioral

ANB 3 times per day for 5-10 minutes per session over a 7-day period

Primary outcomes

  1. Severity of Nausea and Vomiting

    Time frame: Day 7

    Measured by the change in the Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score, where scores range from 3-15, and a higher score indicates greater severity of nausea and vomiting.

Study contacts

Contact information is provided by the study sponsor or research team.

Erin Wesley

CONTACT

[email protected]

612-624-9208

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 30, 2026
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.